|
|
|
 |
| Location: Home -
Products - API Intermediates - API Intermediates
|
Laropiprant(MK-0524)
| Catalogue No. : |
C13800 |
| Product Name: |
Laropiprant(MK-0524) |
| Synonym: |
MK 0524 |
| Chemical Name: |
(3R)-4-[(4-Chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)cyclopent[b]indole-3-acetic acid |
| CAS No. : |
571170-77-9 |
| Structure : |
|
| Molecular Formula: |
C21H19ClFNO4S |
| Molecular Weight: |
435.90 |
| Purity: |
>99% |
| Usage: |
MK 0524 is a potent, selective DP1 receptor antagonist with Ki values of 0.57 nM and 0.75 µM for the DP1 and DP2 receptors, respectively. It inhibits PGD2-induced accumulation of cAMP in both washed platelets and platelet-rich plasma with IC50 values of 0.09 and 4.0 nM, respectively. In a sheep model of allergic rhinitis, 0.1 mg/kg MK 0524 completely blocked PGD2-induced nasal congestion. At a dose of 4 mg/kg, MK 0524 suppressed a nicotinic acid-induced vasodilatory response by 80% in a murine model of flushing, an undesirable side-effect of niacin treatment for dyslipidemia. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
